Business Context and Reporting Period
Company: Minerva Neurosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2015
Subject: Regulation FD Disclosure regarding an update on the product candidate MIN-202 (JNJ-42847922), a selective orexin-2 receptor antagonist under joint development with Janssen Pharmaceutica NV.
Key Financial Metrics
This filing is a current report regarding a scientific update and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing discloses the presentation of preclinical and single ascending dose clinical data for MIN-202 by Janssen at the 29th Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2015) held June 6-10, 2015. No financial material changes are reported in this document.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) detailing the clinical candidate status of MIN-202 for the treatment of insomnia based on data presented at SLEEP 2015.
Legal Disclaimer: The information contained in this report and the accompanying press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any other Company filings.
Risks: No specific risks or contingencies are detailed in the body of this 8-K, though the nature of clinical development implies standard risks associated with drug development.
Investor Verification Checklist
- Review the full text of the press release furnished as Exhibit 99.1 for specific clinical data details.
- Verify the status of the joint development agreement with Janssen Pharmaceutica NV regarding MIN-202.
- Consult the Company's most recent 10-K or 10-Q for financial position and cash runway, as this 8-K contains no financial data.